These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 32060511)

  • 21. Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis.
    Kelly R; Zoubiane G; Walsh D; Ward R; Goossens H
    Lancet Infect Dis; 2016 Apr; 16(4):431-40. PubMed ID: 26708524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cheat sheet to navigate the complex maze of pharmaceutical exclusivities in Europe.
    Tomas MC; Peng B
    Pharm Pat Anal; 2017 Jul; 6(4):161-170. PubMed ID: 28696178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating for-profit public benefit corporations as an additional structure for antibiotic development and commercialization.
    Outterson K; Rex JH
    Transl Res; 2020 Jun; 220():182-190. PubMed ID: 32165059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines.
    Outterson K
    Health Aff (Millwood); 2021 Nov; 40(11):1758-1765. PubMed ID: 34724432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial sensitivity--A natural resource to be protected by a Pigouvian tax?
    Vågsholm I; Höjgård S
    Prev Vet Med; 2010 Aug; 96(1-2):9-18. PubMed ID: 20570379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Public-private partnership models in France and in Europe.
    Demotes-Mainard J; Canet E; Segard L
    Therapie; 2006; 61(4):325-34, 313-23. PubMed ID: 17124948
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of vaccines on antimicrobial resistance.
    Buchy P; Ascioglu S; Buisson Y; Datta S; Nissen M; Tambyah PA; Vong S
    Int J Infect Dis; 2020 Jan; 90():188-196. PubMed ID: 31622674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Encouraging Sustainable Use of Antibiotics: A Commentary on the DRIVE-AB Recommended Innovation Incentives.
    Morel CM; Edwards SE
    J Law Med Ethics; 2018 Jun; 46(1_suppl):75-80. PubMed ID: 30146962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gonorrhoea and gonococcal antimicrobial resistance surveillance networks in the WHO European Region, including the independent countries of the former Soviet Union.
    Unemo M; Ison CA; Cole M; Spiteri G; van de Laar M; Khotenashvili L
    Sex Transm Infect; 2013 Dec; 89 Suppl 4():iv42-6. PubMed ID: 24243879
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Perspective on Incentives for Novel Inpatient Antibiotics: No One-Size-Fits-All.
    Bhatti T; Lum K; Holland S; Sassman S; Findlay D; Outterson K
    J Law Med Ethics; 2018 Jun; 46(1_suppl):59-65. PubMed ID: 30146959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence to European Association of Urology Guidelines on Prophylactic Antibiotics: An Important Step in Antimicrobial Stewardship.
    Cai T; Verze P; Brugnolli A; Tiscione D; Luciani LG; Eccher C; Lanzafame P; Malossini G; Wagenlehner FM; Mirone V; Bjerklund Johansen TE; Pickard R; Bartoletti R
    Eur Urol; 2016 Feb; 69(2):276-83. PubMed ID: 26001610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimicrobial resistance and antibiotic stewardship programs in the ICU: insistence and persistence in the fight against resistance. A position statement from ESICM/ESCMID/WAAAR round table on multi-drug resistance.
    De Waele JJ; Akova M; Antonelli M; Canton R; Carlet J; De Backer D; Dimopoulos G; Garnacho-Montero J; Kesecioglu J; Lipman J; Mer M; Paiva JA; Poljak M; Roberts JA; Rodriguez Bano J; Timsit JF; Zahar JR; Bassetti M
    Intensive Care Med; 2018 Feb; 44(2):189-196. PubMed ID: 29288367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Not Available].
    Ploy MC; Andremont A; Valtier B; Le Jeunne C;
    Therapie; 2020; 75(1):7-12. PubMed ID: 31987590
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 'Tax pharma companies if they fail to act on AMR', says Review chief Lord O'Neill.
    Vet Rec; 2018 Jun; 182(26):728. PubMed ID: 29954991
    [No Abstract]   [Full Text] [Related]  

  • 36. Global geographic trends in antimicrobial resistance: the role of international travel.
    Frost I; Van Boeckel TP; Pires J; Craig J; Laxminarayan R
    J Travel Med; 2019 Dec; 26(8):. PubMed ID: 31115466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Valuing antibiotics: The role of the hospital clinician.
    Masterton RG; Bassetti M; Chastre J; MacDonald AG; Rello J; Seaton RA; Welte T; Wilcox MH; West P
    Int J Antimicrob Agents; 2019 Jul; 54(1):16-22. PubMed ID: 31085298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Value of hospital antimicrobial stewardship programs [ASPs]: a systematic review.
    Nathwani D; Varghese D; Stephens J; Ansari W; Martin S; Charbonneau C
    Antimicrob Resist Infect Control; 2019; 8():35. PubMed ID: 30805182
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibiotic prescription for febrile children in European emergency departments: a cross-sectional, observational study.
    van de Maat J; van de Voort E; Mintegi S; Gervaix A; Nieboer D; Moll H; Oostenbrink R;
    Lancet Infect Dis; 2019 Apr; 19(4):382-391. PubMed ID: 30827808
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incentives to promote the US pharmaceutical innovation: empirical research based on the case of Epogen.
    Zhang L; Wang J
    Drug Dev Ind Pharm; 2021 May; 47(5):820-824. PubMed ID: 34056986
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.